Head-to-head evidence
efsubaglutide alfa vs TG103
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
efsubaglutide alfa
Developed by Shanghai Yinnuo Pharmaceutical Technology
NCT06732960 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but each dose cohort was small, with approximately 10 participants per cohort and a 8:2 active-to-placebo allocation. Because the registry provides no primary endpoint results, it is not possible to determine whether the weight-loss comparison was met.
Next expected readout: November 2026 · NCT07163650 (registry estimate)
TG103
Developed by CSPC Pharmaceutical Group
NCT05997576 · Phase 3 · completed
The study was randomized, double-blind, and placebo-controlled, with 675 participants and clinical primary outcomes measuring weight loss. However, no trial results are posted, so whether the primary endpoints were met cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efsubaglutide alfa's landscape · TG103's landscape